NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Upper GI: HCC - BCLC stage B intermediate disease

Free question published 13 November 2026

Upper GIHCC - BCLC stage B intermediate disease

A 66-year-old man with Child-Pugh A5 cirrhosis has multinodular hepatocellular carcinoma confined to the liver, with no vascular invasion and no extrahepatic spread, ECOG performance status 0. The largest lesion is 5 cm and there are four nodules. He is not a candidate for resection or transplantation owing to tumour distribution. What is the most appropriate first-line treatment for BCLC stage B disease?

  1. ALiver transplantation
  2. BAtezolizumab plus bevacizumab
  3. CSorafenib
  4. DTransarterial chemoembolisation (TACE)
  5. EBest supportive care

Why D is correct

Intermediate-stage (BCLC B) hepatocellular carcinoma - multinodular disease confined to the liver without vascular invasion or extrahepatic spread, in a patient with preserved liver function and good performance status who is not a candidate for curative therapy - is typically treated with transarterial chemoembolisation (TACE), as recommended in the ESMO guideline.

And why the others are not

  • ATransplantation is a curative option for early-stage (BCLC 0/A) disease within criteria; multinodular distribution here precludes it.
  • BAtezolizumab plus bevacizumab is first-line systemic therapy for advanced (BCLC C) disease, not the standard first-line treatment for liver-confined BCLC B disease.
  • CSorafenib is a systemic agent for advanced disease, superseded by atezolizumab-bevacizumab, and not first-line for BCLC B.
  • EBest supportive care is inappropriate for a fit patient with preserved liver function and treatable intermediate-stage disease.

Source ESMO Clinical Practice Guideline - Hepatocellular carcinoma (diagnosis, treatment and follow-up) — Vogel A, Martinelli E, et al; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(6):801-805.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing